IMMUTEP LTD-SP ADR (IMMP) Stock Price, Quote, News and Overview
NASDAQ:IMMP - Nasdaq - US45257L1089 - ADR - Currency: USD
IMMP Quote, Performance and Key Statistics
IMMUTEP LTD-SP ADR
NASDAQ:IMMP (1/27/2025, 8:06:26 PM)
After market: 1.9304 -0.01 (-0.49%)1.94
-0.03 (-1.27%)
The current stock price of IMMP is 1.94 USD. In the past month the price decreased by -0.51%. In the past year, price decreased by -8.06%.
IMMP Latest News, Press Releases and Analysis
Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761
Favourable safety profile for world’s first LAG-3 agonist, IMP761, with no treatment related adverse events to dateAdditional safety data and assessment of...
Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024
Data shows strong overall survival, progression-free survival, and durability from novel combination of efti in combination with pembrolizumab in...
Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial
Immutep's INSIGHT-003 Phase 1 trial reports promising survival data for 1L NSCLC treatment using eftilagimod alpha, Keytruda, and chemotherapy.
Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer
Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer
Media Release Mature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical controls and exceeding...
Immutep Quarterly Activities Report Q1 FY25
Positive feedback received from US FDA regarding the planned TACTI-004 Phase III in first-line non-small cell lung cancer successfully concluding...
IMMP Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.46 | 312.61B | ||
| AMGN | AMGEN INC | 14.72 | 152.09B | ||
| GILD | GILEAD SCIENCES INC | 21.52 | 118.83B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 870.35 | 114.31B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.07 | 75.24B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.80B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.69B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.86B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.98B | ||
| NTRA | NATERA INC | N/A | 21.82B | ||
| BIIB | BIOGEN INC | 9.11 | 21.68B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.34B |
Related stock screener links
About IMMP
Company Profile
Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. The company is headquartered in Sydney, New South Wales. The firm is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.
Company Info
IMMUTEP LTD-SP ADR
Level 32, Suite 32.07 Australia Square, 264 George Street
Sydney NEW SOUTH WALES 2000 AU
CEO: Marc Voigt
Employees: 31
Company Website: https://www.immutep.com/
Investor Relations: http://www.immutep.com/investors-media/whats-new.html
Phone: 61283157003
IMMP FAQ
What is the stock price of IMMP?
The current stock price of IMMP is 1.94 USD.
What is the symbol for IMMUTEP LTD-SP ADR stock?
The exchange symbol of IMMUTEP LTD-SP ADR is IMMP and it is listed on the Nasdaq exchange.
On which exchange is IMMP stock listed?
IMMP stock is listed on the Nasdaq exchange.
Is IMMP a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for IMMP, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of IMMP.
Does IMMP stock pay dividends?
IMMP does not pay a dividend.
When does IMMP stock report earnings?
IMMP will report earnings on 2025-02-20.
What is the Price/Earnings (PE) ratio of IMMP?
IMMP does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.19).
What is the Short Interest ratio of IMMP stock?
The outstanding short interest for IMMP is 3.63% of its float.
IMMP Technical Analysis
IMMP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IMMP. IMMP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
IMMP Financial Highlights
Over the last trailing twelve months IMMP reported a non-GAAP Earnings per Share(EPS) of -0.19. The EPS decreased by 20.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -21.19% | ||
| ROE | -22.54% | ||
| Debt/Equity | 0.01 |
IMMP Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to IMMP. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of -27.08% and a revenue growth -42.33% for IMMP